AbbVie Says Canada's Drug Agency Has Issued Its First-Ever Time-limited Reimbursement Recommendation For EPKINLY (Epcoritamab)
AbbVie Says Canada's Drug Agency Has Issued Its First-Ever Time-limited Reimbursement Recommendation For EPKINLY (Epcoritamab)
This recommendation recognizes the unmet need of adult patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) after two or more lines of systemic therapy and who have previously received or are unable to receive CAR-T cell therapy.
该建议意识到复发性或难治性弥漫大B细胞淋巴瘤(adult patients with Relapsed or Refractory Diffuse Large b-Cell Lymphoma，简称 R/R DLBCL)成人患者在接受两种或更多系统治疗后以及之前接受或无法接受CAR-T细胞疗法的未满足需求。
EPKINLY has also received a positive recommendation for the same indication from INESSS to list it in Quebec contingent on submission and reassessment of phase III clinical data once available.
EPKINLY也收到了INESSS的相似推荐，该机构为魁北克列出了条件，要求一旦Phase III临床数据可获得就进行提交和重新评估。
EPKINLY is being co-developed by AbbVie and Genmab as part of their oncology collaboration.
EPKINLY是AbbVie和genmab的一部分，在他们的肿瘤学合作中共同开发。